New pill could help type 1 diabetes patients cut insulin use and stabilize blood sugar
NCT ID NCT07186660
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This phase 2 trial tests an experimental drug called CIR-0602K in 40 adults with type 1 diabetes who already use an automated insulin delivery system. The drug aims to improve how the body responds to insulin, helping people spend more time in a healthy blood sugar range and possibly reduce their daily insulin dose. Participants will be randomly assigned to receive either the drug or a placebo for several weeks, and researchers will track glucose levels, insulin use, and heart health markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR HEALTH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Virginia
RECRUITINGCharlottesville, Virginia, 22908, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CIR-0602K (a mitochondrial pyruvate carrier inhibitor)
What this could lead to
If it works, this could help people with type 1 diabetes spend more time in their target glucose range and need less insulin each day.
What could go wrong
This is a small, early-phase trial with only 40 participants. The drug may not improve glucose control or could cause side effects. More studies are needed before it could become available.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.